Trial Profile
Apatinib mesylate tablets combined with gefitinib in the treatment of non-small cell lung cancer with gefitinib T790M mutation, single center, open, single arm clinical study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 15 Jan 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Jan 2018 New trial record